OBJECTIVE: To investigate whether weight adjusted cipro¯oxacin dosing results in comparable target site concentrations in obese and lean subjects. DESIGN: Comparative study in two populations. SUBJECTS: Twelve obese subjects (mean weight 122 AE 22.6 kg, 28 ± 52 y, maleXfemale ratio 4X8) and 12 age-and sex-matched lean controls (mean weight 59 AE 8.6 kg). METHODS: Sampling of interstitial space¯uid by means of calibrated in vivo microdialysis after a weight-adjusted intravenous bolus dose of 2.85 mgakg cipro¯oxacin. Analysis of drug concentration by high pressure liquid chromatography. RESULTS: We found signi®cantly higher peak and trough levels of cipro¯oxacin in plasma for obese subjects (9.97 AE 5.64 and 0.44 AE 0.10 mgaml vs 2.59 AE 1.06 and 0.19 AE 0.09 mgaml in lean subjects, P`0.05), while concentration ± time curves of interstitial¯uid of muscle and subcutaneous fat did not differ between the groups. Tissue penetration, expressed as AUC tissue aAUC plasma ratio was signi®cantly lower in obese subjects (0.45 AE 0.27 vs 0.82 AE 0.36, P`0.01). CONCLUSION: We conclude that the penetration process into the interstitial space¯uid is impaired in obese subjects. Therefore antibiotic doses need not be adjusted for an increase in fatawater ratio. Weight-adjusted dosing based on actual body weight will yield adequate tissue levels for cipro¯oxacin.
Introduction
Dose adjustments based on body weight in adults are not routinely employed in clinical practice. While this clearly risks underdosing in overweight or obese patients, there is considerable discrepancy about how to correctly adjust doses. In particular it is not clear whether doses should be based on actual body weight (ABW) or the ideal weight (IBW) of the patient. A review of the English-language literature on antimicrobial pharmacokinetics and dosing in obesity 1 showed that only a limited body of evidence is available on the actual effects of obesity on pharmacokinetics and clinical ef®cacy of most antimicrobials.
An empirical approach for dose adjustments in obese patients is based on the ideal body weight of the patient, calculated according to the Devine formula, 2 to which a dosing weight correction factor (DWCF) of 0.3 times the difference between ABW and IBW is added, since approximately 30% of adipose tissue is composed of water. Clinical studies suggest a DWCF of approximately 0.40 for aminoglycosides 2 and 0.45 for quinolones. Other authors recommend a modi®cation of the dosing interval rather than of daily dose for aminoglycosides. 3 One important limitation of these approaches is related to the fact that they do not account for the effect of the drug distribution process which might be substantially altered in obesity. As most infectious processes take place in the tissue, concentrations measured at this effect site rather than in plasma will determine the clinical effectivity of an antibiotic. Although target site concentrations were hardly accessible to date, the microdialysis technique recently generated an opportunity to selectively measure the concentration of substances in the interstitial compartment, thus revealing important information on the antibiotic concentration at the anatomical target site. 4, 5 This technique provides the possibility of relating dosing regimens to the concentrations in the interstitial compartment of any tissue of interest.
To validate the suitability of ABW-adapted dosing in obese subjects we compared interstitial compartment concentrations of cipro¯oxacin in skeletal muscle and subcutaneous adipose tissue of obese and lean subjects after an ABW based bolus dose of cipro¯oxacin. We employed microdialysis to selectively measure interstitial¯uid concentrations. Ciprooxacin was chosen as a study drug because of its broad antimicrobial spectrum and excellent tissue penetration making it a frequently used drug in soft tissue infections.
Methods

Subjects
The study was approved by the local ethics committee. All volunteers were given a detailed description of the study, and their written consent was obtained. The study was performed in accordance with the Declaration of Helsinki and the Good Clinical Practice Guideline of the European Commission. Twenty-four healthy, drug-free volunteers, 28 ± 52 y of age were enrolled in the study. Twelve volunteers (eight female and four male) were obese with a body weight of 122 AE 22.6 kg and a body mass index (BMI) of 41.0 AE 7.8. The control group consisted of 12 age-and sex-matched volunteers with normal weight (59 AE 8.6 kg, BMI 19.8 AE 1.4). The ideal body weight, calculated using the Devine formula, was 65 kg in both groups.
Volunteers were con®ned to bed-rest for the duration of the study. They were placed in a supine position with the chest tilted up for comfort. No activities apart from reading, watching TV and knitting were allowed. Subjects were fasted until 1 h after the bolus injection of cipro¯oxacin, after that, breakfast and later lunch were served.
Microdialysis experiments
The principles of microdialysis have been described in detail previously. Microdialysis is based on sampling of analytes from the extracellular space by means of a semipermeable membrane at the tip of a microdialysis probe. In this study, probes were implanted in the middle third of the anterior aspect of the right thigh. The probe is constantly perfused with a physiological solution at a low¯ow-rate (1.5 mlamin). Once the probe is implanted into the tissue, substances present in the extracellular¯uid at concentration (C tissue ) diffuse out of the extracellular¯uid into the probe, resulting in a concentration (C dialysate ) in the perfusion medium. Samples are collected and analyzed. For most analytes, equilibrium between extracellular tissue¯uid and the perfusion medium is incomplete, therefore C tissue b C dialysate . The factor by which the concentrations are interrelated is termed recovery.
Recovery assessment
To obtain interstitial concentrations from dialysate concentrations, recovery was assessed with the retrodialysis method. The principle of this method relies on the assumption that the diffusion process is quantitatively equal in both directions through the semipermeable membrane. Therefore, the study drug was added to the perfusion medium in a concentration of 30 mgaml and the disappearance rate through the membrane was taken as the in vivo recovery.
In the present study each subject received cipro¯oxacin (Ciproxin 1 200 mg Infusions¯asche, Bayer Austria, Vienna, Austria) as a single i.v. dose of 2.85 mgakg over 20 min and plasma and interstitial¯uid were sampled at 20 min intervals for 6 h thereafter.
Analysis
Cipro¯oxacin plasma and interstitial tissue levels were measured by high pressure liquid chromatography (HPLC, Shimadzu, Japan) according to a previously described method. 6 Pharmacokinetic calculations Data were ®tted by a commercially available computer program (Kinetica) using a two-compartment model for plasma values and a one-compartment model for tissue values. The following pharmacokinetic parameters were determined: area under the concentration ± time curve (AUC), time to maximum concentration (t max ), maximum concentration (C max-calc ) and mean residence time (MRT), ie the mean time a single molecule resides in a compartment. Penetration ratios for tissues were determined as AUC tissue aAUC plasma .
Statistical analysis
For correlations or comparisons between pharmacokinetic parameters of different compartments Mann ± Whitney Utests were employed, as pharmacokinetic parameters were non-normally distributed. P`0.05 was considered the level of signi®cance. Coef®cients of variation (CV) were calculated as 100 Á s.d. Á mean 71 .
Results
Plasma pharmacokinetic data ABW-adjusted doses of cipro¯oxacin resulted in C max-calcvalues of 9.97 AE 5.64 mgaml and 2.59 AE 1.06 mgaml in obese and lean subjects, respectively (n 24, P`0.05, Figure 1) . Mean levels after 6 h were 0.44 AE 0.10 and 0.19 AE 0.09 mgaml in obese subjects and in controls, respectively (P`0.05). Key pharmacological parameters for plasma data are shown in Table 1 .
Cipro¯oxacin tissue concentrations in obese subjects UM Hollenstein et al
Pharmacokinetic data in the interstitial space¯uid Mean interstitial space¯uid concentration versus time curves are displayed in Figure 1 . For interstitial space¯uid of skeletal muscle tissue, C max-calc -values were 2.16 AE 1.92 and 1.72 AE 0.89 mgaml for obese subjects and controls, respectively (n 24, P NS). These levels declined to 0.11 AE 0.08 and 0.06 AE 0.04 mgaml after 6 h. There was no statistical difference in interstitial space¯uid concentrations between the two groups. Similar AUC values were obtained for both (2.57 AE 1.38 mg Á minaml in obese subjects and 2.28 AE 0.83 mg Á minaml for lean subjects, P NS). Tissue penetration, expressed as AUC tissue aAUC plasma ratio, was lower in obese subjects (0.45 AE 0.27 vs 0.82 AE 0.36, P`0.01). The C tissue aC plasma ratio vs time pro®le was approximately two-fold lower in obese subjects than in lean controls throughout the entire observation period (Figure 2) .
C max-calc -values in the interstitial¯uid of subcutaneous adipose tissue were 3.10 AE 3.29 and 2.12 AE 1.30 mgaml in obese subjects and in controls, respectively. Cipro¯oxacin concentrations at 6 h after infusion of weight-adjusted doses were 0.09 AE 0.06 and 0.05 AE 0.05 mgaml (P NS). The AUC Cipro¯oxacin tissue concentrations in obese subjects UM Hollenstein et al was 2.68 AE 1.85 and 2.21 AE 1.59 mg Á minaml for obese and for lean subjects, respectively (P NS). Tissue penetration, expressed as AUC tissue aAUC plasma ratio, was lower in obese subjects; however, this difference did not reach statistical signi®cance (0.46 AE 0.36 vs 0.85 AE 0.78, P 0.05); see Figure 2 .
Discussion
In the present study we set out to compare interstitial tissue levels of cipro¯oxacin in healthy obese subjects with those in lean controls. The rationale for measuring interstitial¯uid concentrations by microdialysis in skeletal muscle and subcutaneous adipose tissue is based on the fact that obese patients are especially prone to postoperative infectious complications, 7, 8 with the majority being wound and soft tissue infections. As most infections do not take place within cells but in the interstitial space¯uid of tissue, antibiotic concentrations at this target site will determine the clinical outcome. Interstitial¯uid in this study was sampled with microdialysis, a method that allows to selectively collect interstitial space¯uid and to determine concentrations that are not confounded by intracellularly accumulating drug. Cipro¯oxacin was chosen as a study drug since it is commonly employed for the treatment of soft tissue infections, due to its broad antibacterial spectrum covering most clinically relevant organisms.
The main ®nding of our study is that interstitial tissue concentrations were not signi®cantly different in obese subjects compared to lean controls. This held true for both tissues studied, ie skeletal muscle and subcutaneous adipose tissue. Accordingly, the AUC values in interstitial¯uid did not differ between both study groups.
In plasma, however, we observed AUC values that were signi®cantly higher in obese subjects (see Table 1 and Figure  1 ). This ®nding might be of importance as the frequency of gastrointestinal and central nervous system side effects has been linked to cipro¯oxacin concentrations. In the present study population, however, no increase in such events was noted.
Despite considerable differences in weight, ie 120 and 60 kg, there was no difference in V ss between obese and lean subjects, indicating a similar distribution pattern. Interestingly, however, the AUC tissue aAUC plasma ratio was signi®-cantly lower in obese subjects with penetration ratios of approximately 0.4 and 0.8 for obese and lean subjects, respectively. How could this ®nding be explained? One explanation may be related to the fact that fat cells in obesity are not only more numerous but predominantly hypertrophic and the reduced penetration surface area to volume ratio, ie a relatively decreased capillary surface area, might account for the difference in the penetration ratios. In addition, our ®ndings are in line with previous data showing that obese individuals exhibit a markedly reduced tissue perfusion 9,10 as well as an impaired endothelium-dependent vasodilation, 11 which results in an impaired blood¯ow to connective tissues. To our knowledge this is the ®rst report showing that target site distribution of antibiotics is substantially affected in obese subjects, probably due to an impaired peripheral blood¯ow.
To date only few studies have addressed dosing problems in morbidly obese patients and most of them focussed on antibiotics with a narrow therapeutic index such as the aminoglycosides and glycopeptides.
12 ± 16 Despite considerable variability among the various study populations, consensus dosing weight correction factors (DWCF) for aminoglycosides of 40% of excess body weight (EBW, EBW TBW-IBW) IBW are accepted by most clinicians. 12 Similar DWCF have been proposed for cipro¯oxacin. Allard et al measured cipro¯oxacin plasma concentrations after a dose of 400 mg in obese and normal subjects. 17 Based on the resulting V ss they concluded that cipro¯oxacin dosing should be based on IBW 45% of EBW. However, given the obesity-speci®c changes in drug distribution to target tissues, plasma concentrations cannot adequately predict tissue concentrations. As in our study almost identical cipro¯oxacin tissue levels were achieved following a dose based on ABW, a DWCF-based adjustment of cipro¯oxacin doses could result in comparably low and possibly subtherapeutic interstitial levels.
